AZTherapies Completes COGNITE Phase 3 Alzheimer’s Clinical Trial; Top-Line Data Readout Expected in First Quarter of 2021
18 nov. 2020 08h35 HE
|
AZTherapies, Inc.
Last Patient/Last Visit completed on November 13th enabling full clinical database lock BOSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical...
AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors
01 oct. 2020 08h46 HE
|
AZTherapies, Inc.
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the appointment of Marc de...
AZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing
29 sept. 2020 08h46 HE
|
AZTherapies, Inc.
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6...
AZTherapies Doses First Patient in Phase 2a Study of ALZT-OP1a in Amyotrophic Lateral Sclerosis (ALS)
09 sept. 2020 08h34 HE
|
AZTherapies, Inc.
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the dosing of the first...
AZTherapies Announces the Appointment of Drs. Robert Malenka, Adam Boxer, Vijay Kuchroo and Megan Levings, to Scientific Advisory Board
11 août 2020 08h35 HE
|
AZTherapies, Inc.
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the expansion of its...
AZTherapies Strengthens Board of Directors & Business Advisory Board with New Appointments
22 juil. 2020 08h35 HE
|
AZTherapies, Inc.
Noah Gottdiener of Duff & Phelps and Thierry Porté of J.C. Flowers & Co. join BOD Retired Eli Lilly executive Joseph B. Kelley joins Business Advisory Board BOSTON, July 22, 2020 (GLOBE...
AZTherapies to Present at 22nd Annual BIO CEO & Investor Conference
04 févr. 2020 08h47 HE
|
AZTherapies, Inc.
BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced its participation in the 22nd Annual BIO CEO...
AZTherapies Announces Publication of Data Supporting the Targeting of Neuroinflammation in the Treatment of ALS in Scientific Reports
03 déc. 2019 08h32 HE
|
AZTherapies, Inc.
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS Company expects to advance its re-engineered inhaled cromolyn candidate AZT-101...
AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
06 nov. 2019 16h05 HE
|
AZTherapies, Inc.
BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that Ernest D. Penachio has joined the...
AZTherapies to Present at the 25th Annual BIO-EUROPE® International Partnering Conference
04 nov. 2019 08h45 HE
|
AZTherapies, Inc.
BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that its Director of Business Development,...